Israël – MOH approves sale of CTI BioPharma’s cancer drug

July 27, 2014 5:54 pm0 commentsViews: 24

Source : Google

CTI BioPharma Corp. has won approval from Israeli officials to distribute its Pixuvri drug for certain patients with cancer in Israel.
The Seattle biotech (NASDAQ: CTIC) said this week that the drug, also known as pixantrone, was approved by the Israeli Ministry of Health for sale and distribution.
Pixuvri is indicated for patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have received not more than three previous courses of treatment, the company said.
CTI President and CEO Dr. James Bianco said the Seattle biotech — previously known as Cell Therapeutics— is pleased to expand the availability of the drug.
“We feel Pixuvri fills an important role in the treatment paradigm for patients with aggressive B-cell NHL, and we are focused on increasing access to the treatment for as many patients as possible,” he said in a statement.
Once the Ministry of Health has included Pixuvri in the Israeli National Health Basket of drugs, it will be distributed and marketed in Israel by the Neopharm Group, the Seattle company said.
Dr. Abraham Avigdor, a medical school faculty member at Tel Aviv University, said the approval provides a new option, where none existed before, for certain patients to effectively treat their disease with manageable side effects, according to CTI. He said patients who have relapsed after second-line therapy currently have a poor survival outcome, so it’s important to have additional treatment options available to help patients battle their disease.
In the Netherlands, Pixuvri has been approved for inclusion on the list of reimbursed drugs, CTI said. The Dutch Healthcare Authority and a health care insurance board have approved Pixuvri as an add-on drug for patients who need a third- or fourth-line treatment option for aggressive B-cell lymphoma, the company said.

[Source : bizjournals]

Comment this Post

You must be logged in to post a comment.

Recent Comments